Focused treatment for kidney cancer that has responded to immunotherapy
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving focused treatment (surgery or radiation) to all remaining cancer spots after immunotherapy can improve outcomes in kidney cancer. It's for people whose cancer has responded well to at least 6 months of immunotherapy and has only a few remaining spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called clear cell renal cell carcinoma (or a mix that includes clear cell).
- You have 5 or fewer spots of cancer that have spread beyond the kidney (small spots in the lungs less than 1 cm don't count).
- You've been on immunotherapy (checkpoint inhibitors) for at least 6 months, and your cancer has either stayed the same or shrunk.
- All spots of cancer can be safely treated with surgery or radiation.
- You are generally able to take care of yourself (ECOG score less than 2).
- You need to have a stored tissue sample from before your systemic treatment for comparison.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.